drugset / Trial / NCT02885662
Study of CS-3150 in Patients With Primary Aldosteronism
NaSingle-groupOpen-labelTreatment
Summary
To examine antihypertensive effect and safety of CS-3150 in patients with primary aldosteronism.
Timeline
- Start
- 2016-09
- Primary completion
- 2017-07-20
- Completion
- 2017-07-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CS-3150 | Unknown | 2.5 mg | Oral |
| Subject | CS-3150 | Unknown | 5 mg | Oral |